ClinicalTrials.gg
RecruitingNCT07504341COVID-19Updated Oct 30, 2026

Physiological Finding in Management of COVID 19 Patients

An observational study in COVID-19 (Coronavirus Disease 2019), sponsored by St. Martin De Porress Hospital. Recruiting at 2 sites in Taiwan. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by St. Martin De Porress Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 30, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
15,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in COVID-19 with a site in Taiwan — 12 open to participants now, 13 under way, 7 of them phase 3. COVID-19 · Taiwan.

Planned enrollment
3rd of 22
15,000 · median 465
Started
2026
the only one that year
Observational
22 of 78
4 open now
Primary completion
2027-03
later than 5 of 12 live
Registered
76th of 78
by date
Lead sponsor
3 of 78
St. Martin De Porress Hospital

Among the 78 studies in COVID-19 with a site in Taiwan, this one is the 3rd largest by planned enrollment of the 22 observational ones that give a count, is the only one that started in 2026, is one of 22 observational ones, reaches primary completion later than 5 of the 12 other live ones, and was the 76th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

12 of the 78 studies in COVID-19 with a site in Taiwan are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in COVID-19 with a site in Taiwan, or all of them as a file.
02

Study summary

This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. This study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.

Read the detailed description

This study utilizes physiological indicators of COVID-19 patients, such as blood pressure, heart rate, respiratory rate, and level of consciousness, to develop Shock Index (SI), Mordified Shock Index (MSI), Age Shock Index (Age SI), Age Mordified Shock Index (Age MSI), and Respiratory Adjusted Shock Index (RASI), as well as other physiological indicators, as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. For patients with mild to severe illness, and in response to the shortage of manpower during a large influx of emergency patients, this study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.

03

Conditions studied

  • COVID-19 (Coronavirus Disease 2019)

Browse trials for

Keywords

  • COVID-19
  • shock index
  • mordified shock index
  • Age shock index
  • respiratory adjusted shock index
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The COVID-19 patient received treatment at the hospital between May 2022 and March 2027 from emergency room, OPD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reviewing the patient's medical history, the primary focus was on hospital records and existing physiological parameters such as blood pressure, heart rate, respiratory rate, and level of consciousness. The patient received treatment at the hospital between May 2022 and March 2027

Exclusion criteria

Exclusion Criteria:

  • Excluding patients with incomplete clinical data or missing information in their medical records.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
15,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • COVID-19 patient

    The COVID-19 patients were devided into admission ,OPD groups

    Other: physiological parameters

Interventions

  • Otherphysiological parameters

    systolic blood pressure, diastolic blood pressure , heart rate, respiratory rate , GCS

06

What researchers measure

Primary outcomes

  1. Shock index(SI) in the management of COVID -19

    SI= heart rate / systolic blood pressre

    Time frame: 2022 May to 2027 March

  2. Mordified shock index(MSI) in the management of COVID -19

    MSI=heart rate / mean arterial pressure

    Time frame: 2022 May to 2027 March

  3. Age shock index(Age SI) in the management of COVID -19

    Age shock index =Age x (heart rate / systolic blood pression)

    Time frame: 2022 May to 2027 March

  4. Respiratory adjusted shock index (RASI) in the management of COVID-19

    Respiratory adjusted shock index =(heart rate/systolic blood pression) x (repiratory rate/10)

    Time frame: 2022 may to 2027 March

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Under the privacy of patients the data of medical record can't be shared with others researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Mar 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 31, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Mar 11, 2027
CompletionEst.
Mar 31, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • St. Martin De Porres Hospital · Tainan, Taiwan
Show 1 removed
  • St. Martin De Porres Hospital · Tainan, Taiwan
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    1 site added, 1 site removed
    Show site
    • St. Martin De Porres Hospital · Tainan, Taiwan
    Show 1 removed
    • St. Martin De Porres Hospital · Tainan, Taiwan
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07504341
Lead sponsor
St. Martin De Porress Hospital
Responsible party
Chia-hsi Chen (Physician Emergency Medicine and Critical Medicine, St. Martin De Porress Hospital) — Principal investigator
First posted
Mar 31, 2026
Start date
Apr 1, 2026
Primary completion
Mar 11, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Chia-Hsi Chen, Physician
Contact
urologist3509@gmail.com
886-5-2756000 ext. 3708
Chia-Hsi Chen
Contact
urologist3509@gmail.com
886-5-2756000 ext. 3708
Chia-Hsi Chen, Physician
principal investigator · St. Martin De Porress Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion